In this week’s issue:
- Prostate Cancer Foundation – Movember-PCF Challenge Awards
- Child & Family Research Institute – Scholars of Excellence (reminder)
- Department of Defense – Amyotrophic Lateral Sclerosis Research Program and Ovarian Cancer Research Program Funding Opportunities
- Children’s Heart Foundation – Research in Congenital Heart Disease
- Lupus Research Institute – Distinguished Innovator Awards
- American Society of Tropical Medicine and Hygiene – Robert E. Shope International Fellowship in Infectious Diseases
- Centre for Blood Research Seminar Series – Autoantibodies to cell surface GRP78 promote prostate cancer growth by activating TF procoagulant activity
Deadline: April 30, 2015
The Prostate Cancer Foundation (PCF) is pleased to announce a request for applications for Movember-PCF Challenge Awards for investigations of metastatic, lethal prostate cancer. These
awards will be funded depending on the level of innovation in applications received. High risk, currently unfunded projects are most desired.
At least six (6) Challenge Awards from U.S.-based teams will be funded by money raised in the U.S. by Movember, and given the prestigious designation of ‘Movember-PCF Challenge Awards’. Meritorious applications from outside the U.S. may be considered for funding with other PCF funds.
Please visit the PCF website for full details.
Deadline: April 30, 2015
The CFRI Scholars of Excellence program provides exceptional individuals an opportunity to generate an innovative and independent research program under the mentorship of world-class researchers based at the Child & Family Research Institute (CFRI).
The overall goal of this program is to train recent PhDs, MDs and MD-PhD graduates to conduct clinical/translational research in a collaborative, multi-disciplinary environment with intent to develop future leaders in child health research. The program is designed to attract new talent, and preference will be given to applicants from outside BC.
The program provides scholars with a generous stipend of $70,000/year for 3 – 5 years. In the first two years, additional funds are available for research-related expenses ($10,000/year) and travel expenses to attend conferences ($3,000/year).
For more information, please visit the CFRI Scholars of Excellence website.
Department of Defense – Amyotrophic Lateral Sclerosis Research Program and Ovarian Cancer Research Program Funding Opportunities
Deadline: May 2015, See below
The Department of Defense has recently announced funding opportunities within the Amyotrophic Lateral Sclerosis Research Program (ALSRP) and Ovarian Cancer Research Programs (OCRP).
- Therapeutic Development Award – pre-application deadline: May 11, 2015
- Therapeutic Idea Award – pre-application deadline: May 11, 2015
- Clinical Translational Award – pre-application deadline: May 6, 2015
- Investigator-Initiated Research Award – pre-application deadline: May 13, 2015
- Ovarian Cancer Academy Award – Early-Career – pre-application deadline: May 13, 2015
- Pilot Award – pre-application deadline: May 6, 2015
Full details for ALSRP Opportunities at http://cdmrp.army.mil/funding/alsrp.shtml
Full details for OCRP Opportunities at http://cdmrp.army.mil/funding/ocrp.shtml
Deadline: June 5, 2015
The Children’s Heart Foundation calls upon all investigators to submit research proposals on congenital heart disease by June 5, 2015.
The Medical Advisory Board of The Children’s Heart Foundation will review the proposals by late Fall 2015. Those recommended will receive funding in December 2015.
Investigators should contact The Children’s Heart Foundation for an application, or download an application from our website at www.childrensheartfoundation.org.
Deadline: June 25, 2015
The Lupus Research Institute (LRI) invites applications for its Distinguished Innovator Awards, a global program that will provide outstanding scientists with substantial support for up to four years to conduct novel research into the fundamental causes of lupus and so provide new directions toward a cure or prevention.
Advances across many disciplines have led to novel treatments that aim to suppress the manifestations of lupus. Yet few interventions are being developed that seek to reverse or prevent the disease. LRI Distinguished Innovators will address this gap by pioneering research into the fundamental, causative pathways of lupus.
In pursuit of this goal, the LRI welcomes novel, hypothesis- or discovery-driven proposals in human and/or animal model based lupus research. The research proposal must aim to uncover the fundamental causes of lupus and present a compelling vision of how the discovery would lay the groundwork for a potential cure, prevention, or highly effective therapy.
The expert review panel will judge applications primarily on the novelty and potential of the research proposal, and the strengths and track record of the investigator. Emphasis will be on the rationale for the hypothesis rather than the amount of preliminary data. Continuations of long-term research projects will not be considered.
Successful applicants will be outstanding investigators who have demonstrated creativity and productivity in their field of research. We encourage applications from investigators in diverse disciplines including, but not limited to, immunology, genetics, molecular-, cell- and systems biology. Scientists who have not previously worked in lupus are encouraged to apply, as are researchers working outside the US. Applicants must hold a position at an academic institution.
Annual funding of up to $250,000 per year, for a term of up to four years, will be awarded for approved projects. We anticipate that no more than four Distinguished Innovator Awards will be made in 2015.
For full details and application information, please visit the LRI website.
Deadline: May 6, 2015
The American Society of Tropical Medicine and Hygiene has released Robert E. Shope International Fellowship in Infectious Diseases, a Fellowship that provides support for international training opportunities to full-time post-doctoral fellows (PhD, DVM, MD or equivalent) with positions at N. American institutions who study any tropical infectious disease in arbovirology and/or emerging tropical infectious diseases. Award value is $25,000 for defraying travel costs, living expenses and or research abroad.
For further information, please visit the ASTMH website.
Centre for Blood Research Seminar Series – Autoantibodies to cell surface GRP78 promote prostate cancer growth by activating TF procoagulant activity
Date & Time: April 1, 2015, 12-1pm
Location: LSC 3, Life Sciences Centre, 2350 Health Sciences Mall, Vancouver
Dr. Richard C. Austin
Professor of Department of Medicine
Prostate cancer (PC) is one of the most frequently diagnosed cancer types and accounts for fifteen percent of all new cancer cases in men. Age-adjusted incidence rates of PC have dramatically escalated due to the increased availability of screening for prostate-specific antigen (PSA) in men without symptoms of the disease. Current evidence indicates that PC is characterized by a prothrombotic state, occurs on the surface of cancer cells and involves the enhanced expression of tissue factor (TF) and/or its procoagulant activity (PCA). We now have evidence that TF expression/PCA can be modulated in cancer cells by anti-GRP78 autoantibodies. We report, in this study, that anti-GRP78 autoantibody titres are significantly elevated and increase with advanced disease stage in a clinical population diagnosed with PC. Based on these findings, we now propose that the engagement of anti-GRP78 autoantibodies to cell surface GRP78 supports PC growth and metastasis. We previously demonstrated that anti-GRP78 autoantibodies enhance TF expression/PCA in PC cells. In support of these findings, we have shown that the administration of the anti-GRP78 autoantibodies in vivo significantly accelerated tumor growth in NOD/SCID mice. In addition to their effect on TF expression and PCA, we have shown that the binding of anti-GRP78 autoantibodies to cell surface GRP78 activates the unfolded protein response (UPR) in cultured DU145 cells and tumors. The UPR conditions cells to better process physiological insults and promotes the continuous proliferation and survival abilities of the tumor cells. Importantly, this effect on TF-PCA can be alleviated by neutralizing these autoantibodies, or coating cell surface GRP78 with the anticoagulant, heparin.